Orion PharmaDHA:ORIONPHARM +1.41%69 Pretax Margin % is -9.08% as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.38 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 422 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 80.57% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Orion Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was BDT-135 Mil. Orion Pharma's Revenue for the
three
months ended in Mar. 2026 was BDT1,487 Mil. Therefore, Orion Pharma's pretax margin for the quarter that ended in Mar. 2026 was -9.08%.
The historical rank and industry rank for Orion Pharma's Pretax Margin % or its related term are showing as below:
DHA:ORIONPHARM'
s Pretax Margin % Range Over the Past 10 Years
Min: -18.46 Med: 10.23 Max: 11.81
Current: -18.46
DHA:ORIONPHARM's Pretax Margin % is ranked worse than 80.57% of 422
companies
in the Utilities - Independent Power Producers industry
Industry Median: 8.655
vs DHA:ORIONPHARM: -18.46
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Orion Pharma Pretax Margin % Related Terms
Orion Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Pretax Margin % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Pretax Margin % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Pretax Margin % of -9.08% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #340 out of 422 companies in the Utilities - Independent Power Producers industry, placing it in the top 80.6%.
Is Orion Pharma's Pretax Margin % too high?
Orion Pharma's current Pretax Margin % is -9.08%. Based on the distribution chart, Orion Pharma ranks #340 out of 422 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Pretax Margin % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #340 out of 422 companies for Pretax Margin %. This places Orion Pharma in the lower half of its industry. The industry median Pretax Margin % is 8.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for an Utilities - Independent Power Producers company?
The median Pretax Margin % among Utilities - Independent Power Producers companies is 8.66, based on 422 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Pretax Margin % is 8.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Pretax Margin % is -9.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.38, compared to a current price of BDT28.80 — trading 41.3% above its estimated fair value. The current Pretax Margin % is -9.08%. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Pretax Margin % is -9.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.80 is trading 41.3% above its estimated GF Value™ of BDT20.38.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Pretax Margin %: -9.08%
GF Value™: BDT20.38 vs. price of BDT28.80 (41.3% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
